Dengue disease
Therapeutic area
Infectious Disease
Rare disease
Yes
- Definition
- Dengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Dengue disease
- Therapeutic area
- Infectious Disease
- dengue disease
- DF
- Dengue
- Dengue fever
- Dengue virus caused disease or disorder
- Dengue virus disease or disorder
- Dengue virus infection
- Dengue virus infectious disease
- break bone fever
- Philippine hemorrhagic fever
- Singapore hemorrhagic fever
- Thai hemorrhagic fever
- hemorrhagic dengue
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0005502
- Parent condition
- MONDO:0005763
Related records
Broader conditions (9)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Flaviviridae infectious disease
- Human disease
- Infectious disease
- Primary viral infectious disease
- Vector-borne disease
- Viral infectious disease
Narrower conditions (3)
- Asymptomatic dengue
- Dengue hemorrhagic fever
- Dengue shock syndrome
Trials (272)
- A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan
- A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
- A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
- A Controlled Human Infection Model of Dengue
- A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
- A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children
- A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children
- A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants
- A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand
- A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus
- A Pilot Study Examining for the Presence of Fecal Coliforms and Tropical Diseases in Peru
- A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for Dengue
- A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
- A Study of Balapiravir in Patients With Dengue Virus Infection
- A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
- A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
- A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
- A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
- A Study of JNJ-64281802 for the Prevention of Dengue Infection
- A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever
Approved drugs (2)
- Chimeric yellow fever dengue virus, live attenuated
- Dengue virus, live attenuated
Drugs in development (14)
- Aluminum hydroxide Phase 1
- Celgosivir Phase 1
- Cholecalciferol Phase 2
- Diphtheria toxoid Phase 3
- IC14 Phase 2
- Ivermectin Phase 2
- Melatonin Phase 2
- Modipafant Phase 1
- Mosnodenvir Phase 2
- Pertussis vaccine adsorbed Phase 3
- Resomelagon Phase 2
- Sodium chloride Phase 1
- Tetanus toxoid Phase 3
- Zanamivir Phase 2